TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32643500

Group type: EXPERIMENTAL
Intervention: Standard G-CSF administration (24 hours after chemotherapy)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Delayed G-CSF administration (on the day ANC dropped below 1,000/mm3)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Delayed G-CSF administration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard G-CSF administration
Number of subjects: 21
Study: 34684661

Group type: EXPERIMENTAL
Intervention: OMEGA group (20 mL daily dose of dietary formula containing omega-3 and omega-6 PUFAs, vitamin A, vitamin E, and γ-tocopherol)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo group (20 mL placebo containing virgin olive oil)
Number of subjects: 51
Study: 32911210

Group type: EXPERIMENTAL
Intervention: Mindfulness‐based Stress Reduction program (90-95 minutes, twice a week for 12 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness‐based Stress Reduction program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35882018

Group type: EXPERIMENTAL
Intervention: Laparoscopic access by an optical trocar through the new point in the subxiphoid region (Group 1)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Laparoscopic access by an optical subumbilical trocar after Verres needle insufflation (Group 2)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 232

Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 232
Study: 35843540

Group type: EXPERIMENTAL
Intervention: Wheat germ (40 g)
Number of subjects: 50
Study: 35897098

Group type: EXPERIMENTAL
Intervention: 12-month multimodal weight maintenance intervention focusing on nutritional counseling and physical exercises
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Initial weight loss
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Weight maintenance intervention
Number of subjects: 143
Study: 33755508

Group type: EXPERIMENTAL
Intervention: Inoculation with strain Pap009 of Pseudomonas syringae pv. aptata (Psa)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Negative control with phosphate buffer and Carborundum
Number of subjects: 24
Study: 32737004

Group type: EXPERIMENTAL
Intervention: NEXIRI (Irinotecan 120-180 mg/m2 intravenous on days 1 and 15 plus oral Sorafenib 400 mg twice a day)
Number of subjects: 173

Group type: COMPARATOR
Intervention: IRI (Irinotecan 180 mg/m2)
Number of subjects: 173

Group type: COMPARATOR
Intervention: NEX (Sorafenib only)
Number of subjects: 173
Study: 33480852

Group type: EXPERIMENTAL
Intervention: Smartphone app-based intervention used for 28 days offering daily activities based on 10 recommendations to promote positive mental health.
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Smartphone app-based intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 152
Study: 32555996

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control
Number of subjects: 357
Study: 35218370

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg every 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 20
Study: 34763441

Group type: EXPERIMENTAL
Intervention: Manual injection of contrast (N group, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gravity drip administration of contrast media (O group, n=50)
Number of subjects: 100
Study: 35862342

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) with varying parameters (stimulating site, frequency, intensity, pulse number)
Number of subjects: 45
Study: 33217054

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 154

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 154
Study: 35366928

Group type: EXPERIMENTAL
Intervention: Ludangshen oral liquid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 34363470

Group type: EXPERIMENTAL
Intervention: Additional venous reservoir for CO2 drainage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard venous reservoir without additional CO2 drainage
Number of subjects: 10
Study: 32171078

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine plus mefloquine
Number of subjects: 1100

Group type: COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 1100

Group type: COMPARATOR
Intervention: artesunate-mefloquine
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine plus amodiaquine
Number of subjects: 1100

Group type: COMPARATOR
Intervention: artemether-lumefantrine
Number of subjects: 1100
Study: 35608396

Group type: EXPERIMENTAL
Intervention: PAD bundle (pain monitoring and management, light sedation and daily awakening, early mobility, sleep promotion, and delirium monitoring)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: PAD bundle
Number of subjects: 243
Study: 34280355

Group type: EXPERIMENTAL
Intervention: Icotinib 125 mg thrice daily for 2 years
Number of subjects: 322

Group type: COMPARATOR
Intervention: Chemotherapy (vinorelbine and cisplatin or pemetrexed and cisplatin)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 322

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 322
Study: 33262576

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (group N)
Number of subjects: 74
Study: 32852646

Group type: EXPERIMENTAL
Intervention: Te‐PTK with MMC 0.02%
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.03% ointment applied once daily for 2–6 months
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study: 32078926

Group type: EXPERIMENTAL
Intervention: WeChat app-based education and rehabilitation program (WERP)
Number of subjects: 200
Study: 33933667

Group type: EXPERIMENTAL
Intervention: QUIT intervention (cognitive behavioral therapy-based, individual weekly counseling sessions targeting anxiety and depressive symptoms)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Time-Matched Control (TMC) (cognitive behavioral therapy-based, individual weekly counseling sessions)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 180
Study: 33237140

Group type: EXPERIMENTAL
Intervention: Grape juice
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 36293716

Group type: EXPERIMENTAL
Intervention: Wellbeing Training based on Contemplative Practices (WTCP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study: 33878107

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (PE class)
Number of subjects: 120
Study: 34371005

Group type: EXPERIMENTAL
Intervention: Home modifications (handrails for outside steps and internal stairs, grab rails for bathrooms, outside lighting, repairs to window catches, high-visibility and slip-resistant edging for outside steps, fixing of lifted edges of carpets and mats, non-slip bath mats, slip-resistant surfacing for outside areas such as decks)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (no modifications for 3 years)
Number of subjects: 254
Study: 32053547

Group type: EXPERIMENTAL
Intervention: Stroop RT assessment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Single-task assessments
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Single-leg hop
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dual-task assessments
Number of subjects: 41
Study: 36116485

Group type: EXPERIMENTAL
Intervention: High-potential naphthoquinones (2-chloro-, 2-bromo-, 2,3-dichloro-, and 2,3-dibromo-1,4-naphthoquinone) incorporated into the A1 binding site
Number of subjects: 4

Group type: COMPARATOR
Intervention: Native photosystem I with phylloquinone in the A1 binding site
Number of subjects: 4
Study: 34435610

Group type: EXPERIMENTAL
Intervention: Intercession prayer applied three times during hemodialysis sessions.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no prayer intervention).
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intervention group (with prayer intervention).
Number of subjects: 62
Study: 32074412

Group type: EXPERIMENTAL
Intervention: Antipsychotics treatment
Number of subjects: 421
Study: 32669052

Group type: EXPERIMENTAL
Intervention: Iso-inertial flywheel training (FW)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pneumatic resistance training (PN)
Number of subjects: 18
Study: 32410099

Group type: EXPERIMENTAL
Intervention: Modular Approach to Autism Programming for Schools (MAAPS)
Number of subjects: 0
Study: 36333896

Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/day) for 14 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Albendazole (15 mg/kg/day) for 28 days
Number of subjects: 65
Study: 33585378

Group type: EXPERIMENTAL
Intervention: Liposomal Micronutrient Fortified Body Oil (LMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35215466

Group type: EXPERIMENTAL
Intervention: Morning exercise (AM)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Evening exercise (PM)
Number of subjects: 33
Study: 33275913

Group type: EXPERIMENTAL
Intervention: Optivista (OV) IEE
Number of subjects: 410

Group type: COMPARATOR
Intervention: iScan (IS) IEE
Number of subjects: 410
Study: 35297462

Group type: EXPERIMENTAL
Intervention: 12-week supervised outdoors exercise program followed by a 6-month maintenance phase
Number of subjects: 80
Study: 33285733

Group type: EXPERIMENTAL
Intervention: Danlou tablet (1.5 mg a time, 3 times daily for 28 days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 35514063

Group type: EXPERIMENTAL
Intervention: Referral with navigation intervention (n = 995)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Referral only (n = 559)
Number of subjects: 1554
Study: 33856157

Group type: EXPERIMENTAL
Intervention: Dynamic Socket (DS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ischial Ramus Containment (IRC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Subischial (Sub-I)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Post-study preference
Number of subjects: 13
Study: 32286573

Group type: EXPERIMENTAL
Intervention: Chlamydia psittaci detected in blue-fronted Amazon parrots
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Macroscopic changes observed
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Microscopic lesions observed
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Stained tissue sections (Gimenez technique)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Phylogenetic analyses of ompA gene sequences
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Recommendations based on findings
Number of subjects: 212
Study: 35490461

Group type: EXPERIMENTAL
Intervention: Inulin supplementation for 17 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 35275249

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 I.U.)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 36181541

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 117

Group type: COMPARATOR
Intervention: Clinical prediction model
Number of subjects: 117

Group type: COMPARATOR
Intervention: Individual radiologic characteristic model
Number of subjects: 117
Study: 34378456

Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6 mg
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2199
Study: 34343295

Group type: EXPERIMENTAL
Intervention: Bi-atrial (BA) lesion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Box lesion
Number of subjects: 80
Study: 32630214

Group type: EXPERIMENTAL
Intervention: Exercise training during Christmas (TRAIN group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Discontinued training during Christmas (HOLID group)
Number of subjects: 38
Study: 34961754

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention during chemotherapy (n = 173)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Care as usual (n = 172)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Overall population (n = 419)
Number of subjects: 419
Study: 33715265

Group type: EXPERIMENTAL
Intervention: Late-onset dysferlinopathy patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Early-onset dysferlinopathy patients (control group)
Number of subjects: 48
Study: 32808656

Group type: EXPERIMENTAL
Intervention: Sparse additive model for treatment effect modification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation experiments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application to a dataset from a randomized clinical trial
Number of subjects: 0
Study: 34572935

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000 IU/day)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 36434957

Group type: EXPERIMENTAL
Intervention: Goodform intervention (n = 244)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Control group (n = 244)
Number of subjects: 488
Study: 32697104

Group type: EXPERIMENTAL
Intervention: Intensive outpatient psychosocial treatment (18-week cognitive-behavioral treatment, two 90-min sessions per week)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intensive outpatient psychosocial treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (waitlist)
Number of subjects: 88
Study: 33023920

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 2925
Study: 32223354

Group type: EXPERIMENTAL
Intervention: TCC‐EZ
Number of subjects: 15
Study: 32462746

Group type: EXPERIMENTAL
Intervention: 0–2 days of sexual abstinence (group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3–4 days of sexual abstinence (group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: >4 days of sexual abstinence (group 3)
Number of subjects: 90
Study: 35286322

Group type: EXPERIMENTAL
Intervention: Standard medical therapy (SMT) plus rifaximin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 32
Study: 33939512

Group type: EXPERIMENTAL
Intervention: Email-only treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mail-plus-email treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consumers who switched out of a plan chosen in error
Number of subjects: 0
Study: 36209240

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) administered via telephone
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person Montreal Cognitive Assessment (MoCA)
Number of subjects: 0
Study: 34816747

Group type: EXPERIMENTAL
Intervention: One‐step RX‐MC‐Monoblock
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One‐step Monoblock MC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two‐step RX‐MC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monoblock MC‐NA (no adhesive)‐GFP
Number of subjects: 60
Study: 32111233

Group type: EXPERIMENTAL
Intervention: Mindfulness-based resilience training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control (stress management education)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study: 36233454

Group type: EXPERIMENTAL
Intervention: Sufficient fentanyl (maximum estimated effect site concentration: 7.86 ng/mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Minimum fentanyl (maximum estimated effect site concentration: 1.5 ng/mL)
Number of subjects: 30
Study: 35134703

Group type: EXPERIMENTAL
Intervention: Guided internet‐based self‐help problem solving therapy intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Care-as-usual control group
Number of subjects: 190
Study: 34246457

Group type: EXPERIMENTAL
Intervention: Homeopathic molecule for nausea and vomiting prevention during chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 36302537

Group type: EXPERIMENTAL
Intervention: Colchicine (1.5 mg loading dose, followed by 0.5 mg b.i.d. for 6 days and 0.5 mg q.d. for the second week)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96

Group type: COMPARATOR
Intervention: Colchicine and Control
Number of subjects: 96
Study: 32641154

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg orally once daily (OD) on days 1‐14 or until discharge; reduced to 2 mg OD for patients aged >75 years or with creatinine clearance of 30‐60 ml/min.
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Ravulizumab administered intravenously once according to licensed weight‐based dosing regimen.
Number of subjects: 375

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone.
Number of subjects: 375
Study: 35881983

Group type: EXPERIMENTAL
Intervention: Remote protocol for diabetes prevention intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: In-person protocol for diabetes prevention intervention
Number of subjects: 99
Study: 32689752

Group type: EXPERIMENTAL
Intervention: NIV combined with HFNCO
Number of subjects: 73

Group type: COMPARATOR
Intervention: NIV alone
Number of subjects: 73
Study: 35619152

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Smartphone game follow-up
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Conventional in-person follow-up
Number of subjects: 10000
Study: 32791592

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich saline lavage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline lavage
Number of subjects: 20
Study: 35400605

Group type: EXPERIMENTAL
Intervention: Dystocia Line partograph (n = 114)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Action Line partograph (n = 114)
Number of subjects: 228
Study: 33705671

Group type: EXPERIMENTAL
Intervention: High-Fidelity Simulation (HPS) training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 50
Study: 35803552

Group type: COMPARATOR
Intervention: Anticoagulation alone (Control)
Number of subjects: 381
Study: 32165251

Group type: EXPERIMENTAL
Intervention: OCA 5-10 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: OCA 1.5-3.0 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 34364165

Group type: EXPERIMENTAL
Intervention: WEKA image analysis tool
Number of subjects: 12

Group type: COMPARATOR
Intervention: Colour Deconvolution, SpotStudio, WEKA, LEICA RNA‐ISH algorithm
Number of subjects: 12
Study: 35365239

Group type: EXPERIMENTAL
Intervention: Low-dose DW-MSC (5.0×10^7 cells)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-dose DW-MSC (1.0×10^8 cells)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All groups (TL, TH, C)
Number of subjects: 9
Study: 35946280

Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation (400 μg daily for 12 weeks)
Number of subjects: 48
Study: 34324536

Group type: EXPERIMENTAL
Intervention: High scoring organizations on social value
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: High scoring organizations on environmental value
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: High scoring organizations on application value
Number of subjects: 400

Group type: COMPARATOR
Intervention: Low scoring organizations on social value
Number of subjects: 400

Group type: COMPARATOR
Intervention: Low scoring organizations on environmental value
Number of subjects: 400

Group type: COMPARATOR
Intervention: Low scoring organizations on application value
Number of subjects: 400
Study: 34907435

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Metformin (0.5 g three times daily)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 342
Study: 34135506

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 581

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 581
Study: 35038407

Group type: EXPERIMENTAL
Intervention: Personalized music intervention
Number of subjects: 976
Study: 34346159

Group type: EXPERIMENTAL
Intervention: Weekday allied health service events
Number of subjects: 243549

Group type: COMPARATOR
Intervention: Weekend allied health service events
Number of subjects: 243549
Study: 32972733

Group type: EXPERIMENTAL
Intervention: OS‐IUI treatment cycles
Number of subjects: 868
Study: 32709173

Group type: EXPERIMENTAL
Intervention: Kambin triangle approach (KB group; n = 37)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Subpedicular approach (SP group; n = 38)
Number of subjects: 75
Study: 35786815

Group type: EXPERIMENTAL
Intervention: Vivity group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Monofocal group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: AT Lara group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Symfony group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: LDI and BFC Rad
Number of subjects: 88
Study: 34352073

Group type: EXPERIMENTAL
Intervention: Smart glasses group
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study: 35145945

Group type: EXPERIMENTAL
Intervention: TTM-based health intervention
Number of subjects: 400
Study: 33086597

Group type: EXPERIMENTAL
Intervention: 1–2 meals per day
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Low-fat milk consumption
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Fruit consumption
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Vegetable consumption 1–2 times/week
Number of subjects: 800
Study: 33730517

Group type: EXPERIMENTAL
Intervention: 0.3 g·kg‐1 body mass sodium bicarbonate (NaHCO3)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 0.03 g·kg‐1 body mass sodium chloride (PLA)
Number of subjects: 11
Study: 34514494

Group type: EXPERIMENTAL
Intervention: Initial invasive treatment (INV)
Number of subjects: 5179

Group type: COMPARATOR
Intervention: Initial conservative treatment (CON)
Number of subjects: 5179